Biggest News Aggregation in the World
๐Ÿ“ฐ Global Study News

Page 5 - Global Study News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Global Study. Real-time updates on events, politics, business and more.

Sobi, Selecta: Phase 3 DISSOLVE Program Of SEL-212 In Chronic Refractory Gout Meets Primary Goal

Swedish Orphan Biovitrum AB or Sobi (SWTUY.PK), a specialised biopharmaceutical company, and Selecta Biosciences, Inc. (SELB) announced Tuesday positive topline results from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout.
Selecta Biosciences Selecta Imm Selecta Biosciences Inc More Such Health News Swedish Orphan Biovitrum Chronic Refractory

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science